Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
EUCR was delisted on the 26th of April, 2023.
37 hedge funds and large institutions have $76.1M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
4% more capital invested
Capital invested by funds: $73.2M → $76.1M (+$2.87M)
5% less funds holding
Funds holding: 39 → 37 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$2.56M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.73M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.6M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$1.58M |
| 5 |
SC
Sculptor Capital
New York
|
+$782K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$4.92M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.4M |
| 3 |
CIM
Cowen Investment Management
New York
|
-$739K |
| 4 |
ICMH
Integrity Capital Management (HK)
Central,
Hong Kong
|
-$96K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$51K |
EUCR Hedge Fund Activity: Q2 2022 in Review
37 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q2 2022, worth a combined $76.1M — up 3.9% from $73.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of EUCR and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 12 added.
The largest buyer was Glazer Capital LLC, adding an estimated $2.56M. The largest seller was Goldman Sachs, cutting an estimated $4.92M.
- 37 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q2 2022, down from 39 in Q1 2022.
- Funds reported $76.1M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q2 2022, up 3.9% quarter-over-quarter.
- 3 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q2 2022 and 4 closed out, a net change of -1 holder.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q2 2022 was Glazer Capital LLC, an estimated $2.56M added.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q2 2022 was Goldman Sachs, an estimated $4.92M sold.
Based on aggregated 13F filings for Q2 2022.